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ABSTRACT
Introduction Delirium is a potentially preventable disorder 
characterised by acute disturbances in attention and cognition 
with fluctuating severity. Postoperative delirium is associated 
with prolonged intensive care unit and hospital stay, cognitive 
decline and mortality. The development of biomarkers for 
tracking delirium could potentially aid in the early detection, 
mitigation and assessment of response to interventions. 
Because sleep disruption has been posited as a contributor 
to the development of this syndrome, expression of abnormal 
electroencephalography (EEG) patterns during sleep and 
wakefulness may be informative. Here we hypothesise that 
abnormal EEG patterns of sleep and wakefulness may serve as 
predictive and diagnostic markers for postoperative delirium. 
Such abnormal EEG patterns would mechanistically link 
disrupted thalamocortical connectivity to this important clinical 
syndrome.
Methods and analysis P- DROWS- E (Prognosticating 
Delirium Recovery Outcomes Using Wakefulness and Sleep 
Electroencephalography) is a 220- patient prospective 
observational study. Patient eligibility criteria include 
those who are English- speaking, age 60 years or older 
and undergoing elective cardiac surgery requiring 
cardiopulmonary bypass. EEG acquisition will occur 1–2 
nights preoperatively, intraoperatively, and up to 7 days 
postoperatively. Concurrent with EEG recordings, two times 
per day postoperative Confusion Assessment Method 
(CAM) evaluations will quantify the presence and severity 
of delirium. EEG slow wave activity, sleep spindle density 
and peak frequency of the posterior dominant rhythm will 
be quantified. Linear mixed- effects models will be used 
to evaluate the relationships between delirium severity/
duration and EEG measures as a function of time.
Ethics and dissemination P- DROWS- E is approved by 
the ethics board at Washington University in St. Louis. 
Recruitment began in October 2018. Dissemination plans 
include presentations at scientific conferences, scientific 
publications and mass media.
Trial registration number NCT03291626.
INTRODUCTION
Postoperative delirium: a significant clinical 
problem
Delirium is a potentially preventable disorder 
with substantial negative impact on periop-
erative outcomes. Postoperative delirium 
Strengths and limitations of this study
 ► The Prognosticating Delirium Recovery 
Outcomes Using Wakefulness and Sleep 
Electroencephalography study is a prospective ob-
servational study conducted in a perioperative pa-
tient population burdened with a high incidence of 
postoperative delirium.
 ► Longitudinal delirium assessments in tandem with 
electroencephalography (EEG) across diverse states 
of arousal will provide important insight into patient 
trajectories throughout the perioperative period.
 ► Coupling serial delirium assessments with struc-
tured chart review may improve sensitivity for de-
tecting delirium despite its transient and fluctuating 
nature.
 ► Wireless wearable EEG recording devices outfitted 
with dry electrodes allow for data acquisition with 
minimal interference in patient care; however, sen-
sitivity to motion artefact and patient tolerance may 
challenge data acquisition and interpretation.
 ► Prolonged postoperative sedation in the intensive 
care unit may complicate the interpretation of delir-
ium assessments and EEG.
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is associated with prolonged hospitalisation, persistent 
functional decline and mortality.1–6 Moreover, this post-
operative problem is part of a larger problem that costs 
the USA up to $152 billion annually.7 After major cardiac 
and non- cardiac surgery, the incidence of delirium in 
elderly patients is estimated to exceed 25%.8 9 However, 
the condition may be underdiagnosed. First, assess-
ment timing and frequency may compromise detection 
because delirium exhibits a fluctuating course of inat-
tention and disordered cognition. Manifestation peaks 
within the first two postoperative days, but variance in 
onset and recurrence impairs detection across indi-
viduals.10 11 Second, without use of sensitive screening 
instruments, clinicians may underdiagnose the more 
common hypoactive delirium subtype that arises subtly 
as disorganised thinking and disengagement.11–15 Finally, 
subsyndromal delirium may also be difficult to detect as 
patients may show signs without fulfilling all diagnostic 
criteria.16–18 These cases are clinically impactful and have 
been targeted for palliative intervention due to associ-
ated poor outcomes.17–22 Despite this, no quantitative 
biomarkers exist that predict delirium onset, trajectory 
or severity. Identifying such prognostic markers may help 
develop preventative or abortive therapies and may eluci-
date underlying neural mechanisms.
Perioperative sleep disruption: a potential contributor to 
delirium
Sleep addresses critical homoeostatic needs for restoring 
physiological processes such that deficiencies result 
in cognitive decrements and immune and endocrine 
system impairments.23–25 Acute sleep deprivation is 
linked to increases in oxidative stress, increased blood 
brain barrier permeability and reduced clearance of 
extracellular metabolites—all putative mechanisms 
underlying postoperative delirium.26 Furthermore, 
chronic sleep disorders are prevalent in neurodegener-
ative disorders including Alzheimer’s disease (AD) and 
may increase delirium susceptibility.6 27 28 Advanced age 
is also associated with sleep disorder prevalence,29 which 
may increase delirium susceptibility in older adults. In 
the perioperative arena, preliminary actigraphy studies 
suggest an association between abnormal sleep–wake 
cycle patterns and postoperative delirium.30–32 These 
studies have not been followed by large- scale investi-
gations of brain activity to examine the relationship 
between sleep structure and delirium outcomes. This is 
important because sleep may be a modifiable contrib-
utor to postoperative delirium.
Polysomnography (PSG), the gold- standard for studying 
sleep, requires patients to be tethered to amplifiers and 
acquisition computers. This hindrance to patient comfort 
and postoperative rehabilitation has limited perioperative 
studies of sleep. PSG relies on electroencephalographic 
(EEG) waveforms to detect wakefulness and classify sleep 
into distinct stages of rapid eye movement (REM) and 
non- rapid eye movement (NREM) sleep.33 These stages, 
interspersed in cycles throughout sleep, are defined by 
well- known EEG waveforms and corresponding physiolog-
ical processes (figure 1A). For instance, sleep spindles can 
occur in stage N2 sleep, which comprises approximately 
50% of total sleep time. The presence of EEG slow waves 
defines stage N3 sleep, which is associated with restorative 
physiological benefits across multiple organ systems.34–36 
These EEG waveforms facilitate segmentation into sleep 
stages and have characteristics in the frequency domain 
(figure 1B).
Figure 1 Overnight electroencephalography (EEG). A hypnogram acquired with the EEG device reveals cycling of sleep stages 
over an evening with wakefulness (W), rapid eye movement sleep (R) and non- rapid eye movement sleep stages (N1, N2 and 
N3) (A). The corresponding spectrogram shows signal power in the frontal EEG decomposed by frequency as a function of 
time. Slow waves (blue arrow) carry low frequency power during N3 sleep, while sleep spindles (red arrow) have power in higher 
frequencies and occur primarily during N2 sleep (B). Sleep spindles (underlined) occurring at the point designated by the red 
arrow in panel B are reflected by ~13 Hz power (C). Slow waves occurring at the point designated by the blue arrow in (B) are 
reflected by 0.5–4 Hz power (D).
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Despite technical limitations, small studies have 
demonstrated profound postoperative changes in sleep 
architecture with unknown clinical implications. N3 
sleep suppression occurs on the day of anaesthesia in 
volunteer studies and persists on subsequent postopera-
tive nights.37 38 Fragmentation of sleep architecture and 
overexpression of N2 with reduction of N3 and REM 
sleep occur in the first postoperative night following both 
cardiac and non- cardiac surgery.38–45 N3 and REM sleep 
return on the third or fourth postoperative nights.32 38 43 46 
However, the clinical impact of NREM sleep disruption 
remains unclear as EEG waveforms defining different 
sleep stages have not been related to postoperative 
delirium or other perioperative outcomes.
EEG markers of sleep and wakefulness and thalamocortical 
disruption
Sleep stages, characterised by EEG waveform morphology, 
are normally regulated by circadian and sleep homoeo-
static processes.47 48 Preliminary studies in critically ill, 
ventilated patients with delirium have revealed abnormal 
EEG waveform characteristics corresponding to sleep–
wake states. For instance, sleep spindles are absent during 
phenotypic sleep while slow waves are present during 
apparent wakefulness.49 50 Taken together, these data 
suggest that investigating EEG during perioperative sleep 
and wakefulness may aid in correlative studies on the time 
course of delirium onset.
Sleep spindles
Originally described by Loomis et al,51 EEG sleep spindles 
reflect thalamocortical connectivity for sustaining sleep 
and consolidating memory.52 These oscillations in N2 
and N3 sleep (reviewed in Loomis et al53) originate from 
the thalamic reticular nucleus and propagate across the 
cortex with differential expression patterns in occipital 
and frontal EEG.54 55 Sleep spindles possess a waxing and 
waning pattern of at least 0.5 s in duration (figure 1C). 
Within an individual, the dominant frequency of sleep 
spindles in the 9–16 Hz range is conserved.56 Sleep 
spindle expression is under inverse homoeostatic 
control with a reduction in density following acute sleep 
deprivation.57 Sleep spindle density, calculated as the 
number of spindles per unit time, varies over an evening 
of sleep.58 59 This measure may be a useful marker of 
chronic sleep deprivation and cognitive dysfunction; 
decrements mirror the severity of cognitive episodic 
memory dysfunction in AD patients.58 60 Furthermore, 
abnormal sleep spindle expression occurs in patients 
with severe dementia and schizophrenia and is predictive 
of dementia in patients with Parkinson’s disease years 
after measurement.61–64 Analogues of sleep spindles are 
observed during sedation and general anaesthesia with 
an unknown impact on subsequent homoeostatic regu-
lation and expression.65–67 Overall, perioperative sleep 
spindle expression has not been characterised or related 
to perioperative outcomes.
Slow wave activity
Sleep slow waves are characteristic of N3 sleep and may 
be useful for tracking cognitive function.68 They are 
putative markers of synaptic pruning, memory consoli-
dation and have been related to the clearance of beta- 
amyloid and other metabolites.69–72 Sleep slow waves are 
defined through high amplitude, low frequency oscilla-
tions on EEG (figure 1D). In order to correlate cognitive 
function with low frequency oscillation amplitude, sleep 
slow wave activity (SWA) is calculated as the total EEG 
power of contributory low frequencies (eg, 1–4 Hz) per 
minute.73 74 Regional sleep SWA positively correlates with 
learning and subsequent visuomotor task performance75 
that may be impaired by auditory interventions.76 Exog-
enous enhancement of SWA potentiates memory and 
task performance.77 In contrast, selective acute SWA 
deprivation induces a rebound in magnitude on the next 
day based on the preceding deficit.78–80 Furthermore, 
reduced SWA is associated with beta amyloid deposition, 
tau pathology,81 atrophy in prefrontal cortical regions 
and impaired memory.71 82
In adults, slow waves observed during wakefulness83–86 
are usually associated with underlying structural or 
functional pathology.87 Moreover, diffuse slow waves 
may represent disrupted thalamocortical connectivity.88 
Previous work has identified slow waves during apparent 
wakefulness in patients with postoperative delirium.89–91 
Furthermore, low EEG frequency predominance has been 
reported as a non- specific marker of hepatic encephalop-
athy,92–95 sepsis- associated encephalopathy96–99 and post-
operative delirium.89 90 100–109 Slow waves are associated 
with altered thalamocortical connectivity during general 
anaesthesia.110 Whether overexpression of slow waves 
during wakefulness precedes postoperative delirium 
remains unknown.
Posterior dominant rhythm
The posterior dominant rhythm (PDR) is a robust 
marker of thalamocortical connectivity, integrity and 
cognitive function during relaxed wakefulness with eyes 
closed.33 111 112 The PDR consists of oscillations evoked by 
eyelid closure that have greatest amplitude in occipital 
EEG derivations.112 113 For the vast majority of adults, the 
dominant frequency of the PDR lies within the 8–13 Hz 
(alpha) frequency band (figure 2). Lower PDR frequen-
cies observed in AD patients are associated with thalamic 
deficiencies of norepinephrine.114 115 Similarly, low PDR 
frequencies during apparent wakefulness have shown 
promise as a marker of early and advanced cognitive 
impairment of AD.116–120 The severity of slowing appears 
to correlate with the degree of cognitive impairment121–125 
but has not been evaluated longitudinally in the periop-
erative period.
Hypotheses and aims
We hypothesise that delirium is a disorder of both sleep 
and wakefulness resulting from abnormal thalamocor-
tical connectivity. Furthermore, we hypothesise that 
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EEG alterations can predict delirium onset and severity. 
Our specific aims include the following: (1) evaluate 
whether preoperative EEG measures of sleep and wake-
fulness predict postoperative delirium and its severity; 
and (2) assess whether postoperative abnormalities in 
EEG measures of sleep and wakefulness correlate with 
delirium onset, severity and clinical course. For our 
first aim, we hypothesise that the EEG power of preop-
erative sleep slow waves, sleep spindle density and PDR 
frequency will correlate negatively with the peak severity 
of postoperative delirium. Our second aim, focused on 
postoperative findings, addresses three hypotheses: (1) 
delirium onset and peak severity will correlate with an 
increase in SWA and diminished PDR frequency during 
wakefulness; (2) delirium onset and peak severity will 
correlate with the reduction in postoperative sleep 
spindle density relative to preoperative measurements; 
(3) delirium recovery will coincide with a reversion of 




Prognosticating Delirium Recovery Outcomes Using 
Wakefulness and Sleep Electroencephalography 
(P- DROWS- E) is a prospective longitudinal cohort obser-
vational investigation. The Human Research Protection 
Office at Washington University School of Medicine 
approved the study in 2017. P- DROWS- E was regis-
tered prior to enrolment and conforms to the Standard 
Protocol Items: Recommendations for Interventional 
Trials checklist (see online supplemental file 1).
Figure 2 The posterior dominant rhythm (PDR) during eyes closed wakefulness using the electroencephalography (EEG) 
recording device. Alpha oscillations are not easily discernable during eyes open wakefulness (A). During eyes closed 
wakefulness, the PDR in cognitively intact adults is comprised oscillations in the alpha (8–13 Hz) frequency band (B). This 
activity is apparent in the decomposition of these two signals into power at corresponding frequencies by spectral analysis. The 
PDR emerges during eyes closed wakefulness with signal power at ~10 Hz (blue) compared with signal power during eyes open 
(red) (C). A power spectrogram demonstrates quantifiable fluctuations in the ~10 Hz power during epochs of eyes open vs eyes 
closed wakefulness (red vs blue arrow) (D).
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Study participants
We will enrol 220 patients undergoing elective cardiac 
surgery at Barnes- Jewish Hospital, St. Louis, Missouri. 
Inclusion criteria are (1) English- speaking, (2) age 60 
years or older and (3) undergoing elective major cardiac 
surgery requiring cardiopulmonary bypass (eg, coronary 
artery bypass grafting, aortic repair/replacement, septal 
myectomy, Maze procedure and/or heart valve repair/
replacement). Exclusion criteria are (1) undergoing 
surgery requiring deep hypothermic circulatory arrest, 
(2) pre- existing delirium, defined by a positive preop-
erative confusion assessment method (CAM) evaluation 
and (3) inability to participate sufficiently in delirium 
screening due to deafness, blindness or poor English 
fluency. We minimised exclusion criteria to maximise 
generalisability of findings to the general cardiac surgical 
population. Participants will be compensated for their 
efforts: $50 for each preoperative EEG recording and $25 
for each intraoperative and postoperative EEG recording, 
up to $300.
Recruitment
Recruitment and enrolment of eligible patients will occur 
following screening of the cardiac surgery schedule at 
Barnes- Jewish Hospital, the Center for Preoperative 
Assessment and Planning clinic schedule, and inpatient 
census lists from cardiology and cardiothoracic wards by 
study coordinators.
Data collection
Preoperative screening and assessment tools
Baseline sleep–wake function will be evaluated through 
questionnaires including daytime sleepiness with the 
Epworth Sleepiness Scale,126 overall sleep–wake function 
with the Patient Reported Outcomes Measurement Infor-
mation System (PROMIS) Sleep Related Impairment/
Sleep Disturbance Scale,127 sleep quality with the Pitts-
burgh Sleep Quality Index128 and obstructive sleep apnoea 
risk estimation with the Snoring, Tiredness, Observed 
apnea, high blood- Pressure, BMI, Age, Neck circumfer-
ence, and male Gender (STOP- BANG) questionnaire.129
Baseline depression, cognition and prior education are 
prognostic factors for postoperative delirium. Therefore, 
patients will complete the Geriatric Depression Scale 
short form130 and the Montreal Cognitive Assessment, 
which screen for cognitive impairment.131 In addition, 
the AD-8,132 a rapid screen that has been validated against 
AD biomarkers, will be used.133 The number of years of 
education will also be recorded. Finally, the CAM134 and 
serial pain assessments will be performed.
Confusion assessment method
The CAM is used to diagnose delirium based on five key 
domains: (1) acute onset, (2) fluctuating course, (3) inat-
tention, (4) disorganised thinking and (5) altered level 
of consciousness.134 It is a validated tool for delirium 
diagnosis with a sensitivity of 94% and specificity of 
89% against full neuropsychiatric evaluation.135 CAM 
administration takes 10–20 min at our institution and 
consists of a formal patient interview comprised questions 
that identify delirium symptoms and test cognition.
CAM assessments will be performed by researchers 
who have undergone an established rigorous training 
process.136 137 All assessments will be independently 
reviewed by a separate, trained research team member for 
internal scoring consistency and completeness. Ambig-
uous assessments will be reviewed by the research team 
and PI weekly with concomitant adjudication of each 
domain and the overall delirium determination. The 
patient’s family and nurse are also questioned about the 
patient’s postoperative mental status as needed. Patients 
whose medical condition prohibits the use of the CAM 
will be assessed using the CAM for the intensive care unit 
(CAM- ICU) instrument.138 139 Both the CAM- ICU and the 
CAM have been shown have good agreement with the 
Diagnostic and Statistical Manual of Mental Disorders 
(DSM)- IV criteria for delirium.140–142
Pain assessments
A limited number of studies suggest an association 
between acute postoperative pain and delirium.143–145 
Therefore, serial pain evaluations will be completed using 
the Behavioral Pain Scale (BPS)/BPS Non- Intubated and 
the Visual Analog Scale.146 Evaluations will be performed 
after each CAM assessment.
EEG apparatus
Perioperative EEG will be used to assess markers of wake-
fulness, sleep and delirium. To address the technical 
limitations of PSG, we will employ a consumer- grade 
wearable wireless EEG device (Dreem, Rhythm, New York, 
New York, USA) requiring minimal clinical intervention 
and maintenance (figure 3A).147 148 It yields continuous 
multichannel EEG data through dry electrodes, heart rate 
through infrared detectors and head movement through 
accelerometers. In addition to frontal forehead sensors 
(F7, F8 and Fpz), occipital EEG signals are acquired using 
posterior sensors (O1 and O2). Adequate signal quality 
will be assessed by research staff.
Preoperative EEG acquisition
To maximise patient compliance and signal quality, 
research staff will demonstrate wireless EEG device usage. 
Patient head circumference will be measured, and the 
device will be adjusted for proper fit. To obtain baseline 
PDR, patients will be asked to remain still and relaxed for 
4 min with eyes open followed by a 4 min period of eyes 
closed (figure 3B). Patients will demonstrate comprehen-
sion by donning the device and initiating a recording 
themselves.
Patients will be requested to wear the device for up to 
two nights before surgery to allow for EEG sleep structure 
assessment. For inpatients, research staff may assist with 
device application. For outpatients, the device, charger, 
alcohol wipes, an educational video and an instruction 
sheet will be provided. Research staff will also be available 
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by phone to address questions. Patients will be contacted 
by phone to ensure compliance, satisfaction and data 
quality.
Day of surgery EEG acquisition
If necessary, additional preoperative awake EEG data will 
be obtained. The Dreem will then be used throughout 
anaesthetic induction, maintenance and emergence 
(figure 3B). Research staff will optimise EEG acquisition 
through device adjustments, as needed.
Postoperative EEG acquisition, delirium assessments and pain 
scores
Semi- continuous EEG recordings will be acquired up 
to postoperative day (POD) 7, patient withdrawal or 
hospital discharge (figure 3B). To enhance data collec-
tion, participants will be asked to wear the device within 
2 hours of 07:00, 13:00 and 19:00 for 4 min each during 
eyes open and eyes closed periods. The 07:00 and 19:00 
recording sessions will coincide with acquisition of CAM 
and pain scores. CAM- ICU will be used for intubated 
patients.149 EEG but not CAM data will be obtained for 
unresponsive patients (Richmond Agitation- Sedation 
Scale (RASS)150 level −4 or −5). Participants will wear 
the device overnight to provide data on nocturnal sleep 
structure.
Structured chart review for delirium
Coupling structured chart review with CAM/CAM- ICU 
increases sensitivity in detection of delirium without loss 
of specificity.151 152 Therefore, formal structured chart 
reviews will be performed by independent trained clin-
ical researchers who are blinded to EEG and CAM data. 
Reviews will occur daily until POD 7. The chart review 
methodology (table 1) will use patient information 
from the electronic medical record including mental 
status, progress notes, medication usage (including 
psychotropic, sedative and pain medications) and rele-
vant clinical details (eg, length of stay, ICU behavioural 
interventions, extubation and/or re- intubation proce-
dures, etc).151 152 Structured chart review training will be 
adapted from previously published methods,152 and only 
CAM trained staff will be eligible. In cases where chart 
review delirium outcome is uncertain, a consensus review 
will occur. In cases where chart review is discordant with 
both CAM assessments on a given day, a formally trained 
attending clinician blinded to all other metrics will deter-
mine the final outcome.
Analyses
EEG preprocessing and analysis
EEGLAB,153 an open- source analytical suite for MATLAB 
(Mathworks, Natick, Massachusetts, USA), will be used 
Figure 3 Overview of electroencephalography (EEG) device and patient participation workflow. Perioperative EEG will 
be obtained via the Dreem device, a consumer- grade wireless wearable EEG device that records from five sensors, pulse 
oximetry and accelerometry (A). Longitudinal assessments of EEG and delirium symptomatology will occur preoperatively, 
intraoperatively and postoperatively. Following consent in the Center for Preoperative Assessment and Planning/inpatient unit, 
a baseline confusion assessment method (CAM) and EEG are acquired. Postoperative daytime assessments occur within a 
2- hour window surrounding 07:00, 13:00 and 19:00 until postoperative day 7, patient withdrawal or hospital discharge (B). The 
human in this figure is a model and not a patient. Permission was granted for non- commercial use of this image by Dreem.
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for down- sampling deidentfied EEG to 128 Hz after 
band- pass filtering (0.1–50 Hz first order Butterworth). 
Records will undergo visualisation and artefact removal 
using EEGLAB plugins and/or custom- coded MATLAB 
scripts. Multitaper methods will be used for power spec-
tral analysis using the MATLAB Chronux toolbox.154 
Spectral estimates between 0.5 and 30 Hz will be based 
on 6 s non- overlapping time windows, time- bandwidth 
product of 3 and 5 tapers.
Sleep technologist scoring
Records will undergo sleep staging with visualisation in 
Philips Respironics Sleepware G3 Software. They will be 
scored successively with a low frequency filter (LFF) of 
1 Hz then 0.3 Hz and a high frequency filter of 30 Hz. 
The LFF of 1 Hz will attenuate artefacts related to sweat, 
respiration and movement. Rescoring with an LFF of 0.3 
Hz will allow for best quantification of SWA and stage N3 
sleep. Channels Fpz- F8, Fpz- F7 and F8- F7 will be used 
for visual scoring, while occipital derivations will be used 
secondarily. Additionally, accelerometer channels will 
be used to identify movement, respiratory patterns and 
arousals. Registered polysomnographic technologists 
will score the record in 30 s epochs using the modified 
American Association of Sleep Medicine (AASM) criteria 
(table 2).33 Evaluators will be blinded to delirium clin-
ical outcomes and automated scoring provided by the 
manufacturer.
Quantitative measures of sleep spindle and slow waves
Sleep spindles will be scored manually by registered poly-
somnographic technologists using AASM guidelines and 
with the assistance of publicly available algorithms imple-
mented in our laboratory.63 155–162 Spindle density will be 
computed from the number of spindles per minute of N2 
and N3 sleep. Dissipation in sleep spindle power (ie, total 
power across 11–16 Hz) will be assessed over the course 
of nocturnal sleep.
Custom- written MATLAB subroutines will compute the 
SWA as the total absolute spectral power in the 1–4 Hz 
frequency band, calculated in 1 min intervals during N2 
and N3 sleep.163 Custom- written MATLAB code will be 
used to detect individual slow waves and calculate their 
power.164 For our second aim, predictor SWA measure-
ments during phenotypic wakefulness will be computed 
from postoperative recordings where EEG slowing is 
noted despite persistent criteria for wakefulness (eg, eye 
movements, high frequency activity (>30 Hz) and motion 
artefact). Registered sleep technologists will review these 
expected discordant epochs.
Quantitative measures of the PDR
Previously developed MATLAB scripts will be used to 
quantify PDR frequency from EEG recorded during eye 
closure. Registered sleep technologists will first screen 
the occipital EEG (Fpz- O1, Fpz- O2, O1- O2) recorded 
during eyes closed wakefulness (07:00, 13:00 and 19:00) 
to identify recording contamination by sleep. Band- pass 
filtering of the signals will then occur, and spectral esti-
mates will be generated through the Chronux toolbox 
modules.154 PDR frequency will be determined based on 
peak power.
Table 1 Chart abstraction for delirium during hospitalisation
Was delirium diagnosed by a clinical provider?




Was there any evidence in the chart of acute confusion (eg, delirium, mental status change, 
disorientation, hallucinations, agitation, etc)?
(Review all handwritten and electronic notes, flowsheet data, and documented CAM- ICU results 




Was there any documentation of the use of delirium prevention strategies at any time during the 
hospitalisation before delirium occurred?
(Review flowsheet data for nursing interventions such as reorienting patient to room, equipment, 




Was there any documentation of the use of a restraint or bed alarm/device recorded during the 
patient’s stay?









 ► Cannot be 
determined
Outcome is determined after a complete review of the medical record. Questions 1–4 are designed to help the reviewer identify evidence of 
delirium consistent with diagnostic criteria including an acute change or fluctuating course, inattention and disorganised thinking or altered 
level of consciousness.
CAM- ICU, confusion assessment method for the intensive care unit.
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Processing of delirium outcomes
Daily delirium incidence will be coded as a binary vari-
able defined by a positive CAM assessment and/or chart 
review. Delirium duration will be coded as a categorical 
variable defined by the total number of days with a posi-
tive delirium outcome, ranging from 0 to 7. Delirium 
subtype (hypoactive, hyperactive or mixed), based on the 
RASS and the CAM, will also be noted. Delirium severity 
will be quantified using the CAM- S and/or CAM- ICU 7. 
The CAM- S is a validated weighting of CAM sub- scores,165 
with a long- form version ranging from 0 to 19. The 
CAM- ICU-7166 is a validated weighting of the CAM- ICU 
subscore ranging from 0 to 7. Raw severity scores will be 
normalised by the maximum score of the tool in order 
to yield scaled severity scores ranging from 0 to 1. The 
maximum scaled delirium severity score will be coded as 
a continuous variable in analytical models.
Statistical analyses
Linear mixed effects models will be used to evaluate 
relationships between EEG measures and delirium 
severity and duration. For our first aim, principal inde-
pendent variables will include preoperative measures of 
sleep spindle density, sleep SWA for stages N2 and N3, 
and PDR frequency. For our second aim, independent 
variables will include EEG changes relative to preoper-
ative baseline for sleep spindle density, awake SWA and 
PDR frequency. Given that EEG measures may vary by 
age167–169 and sex,163 170 these factors will be included 
as relevant biological variables. Secondary analytical 
models will include relevant medications and comor-
bidities such as obstructive sleep apnea and depression 
as well as years of education. Additional covariates to 
account for intraoperative anaesthetic exposure will use 
intraoperative measures of SWA, sleep spindle density 
and burst suppression171–173 derived from intraoperative 
EEG device recordings. As we expect that only 25% of 
our patients may develop postoperative delirium, we will 
consider zero- inflated models.
Sample size calculations
Considering the heterogeneity of delirium phenotype 
and variable exposure to narcotics and other medica-
tions, we expect a large sample size to reduce the risk of 
completing an underpowered study. Based on preopera-
tive recruitment of 220 patients, we expect 95% capture 
rate for preoperative and intraoperative recordings, and 
a 25% incidence of delirium based on results from the 
Electroencephalography Guidance of Anesthesia to Alle-
viate Geriatric Syndromes (ENGAGES) study,173 with the 
majority completing delirium assessments throughout 
the postoperative period. We expect at least 70% of 
these patients to provide usable postoperative EEG. We 
anticipate the ability to capture at least moderate effects 
(effect size 0.5, beta 0.2, power 0.8) based on conven-
tions for statistical power analysis in the behavioural 
sciences.174
Prespecified substudies
Other physiological markers for predicting delirium outcomes
Additional physiological markers (accelerometry, blinks 
and heart rate measurements), and sleep EEG markers, 
including N1 vertex waves, N2 K- complexes and REM 
sawtooth waves will be evaluated against delirium 
outcomes.
Table 2 Modified American Association of Sleep Medicine scoring criteria for different sleep stages
Stage Criteria/description
W >50% epoch contains any of the following
Posterior dominant rhythm: 8–13 Hz EEG oscillations over occipital region with eyes closed
Eye blinks: vertical eye movements of 0.5–2 Hz
Slow eye movements: conjugate, sinusoidal eye movements
Rapid eye movements: conjugate, irregular, sharply peaked eye movements
N1 Posterior dominant rhythm absent with any of the following
Low amplitude mixed frequency EEG: 4–7 Hz activity
Vertex sharp waves: EEG sharp waves with duration <0.5 s
Slow eye movements: conjugate, sinusoidal or slow eye movements
N2 Either present during the first half of an epoch or last half of previous epoch
K- complexes: EEG negative sharp wave and positive component with total duration >0.5 s and without arousal
Sleep spindles: crescendo- decrescendo EEG oscillatory pattern with frequency 11–16 Hz and duration of 0.5–3 s
N3 Presence over >20% of an epoch
EEG slow waves: delta waves with a frequency 0.5–4 Hz and peak- to- peak amplitude >60 μV
R All of the following present
Low amplitude mixed frequency EEG: 4–7 Hz EEG activity without K- complexes or sleep spindles
Sawtooth waves: EEG train of sharply contoured or triangular waves with frequency of 2–6 Hz
Rapid eye movements: conjugate, irregular, sharply peaked eye movements
NS Epoch cannot be scored due to excessive artefact and/or inability to fulfil criteria for above stages
EEG, electroencephalography.
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Device validation for elderly patients
This substudy will compare Dreem data and PSG in the 
geriatric population to complement early studies across 
a broad age.148
Postoperative cognitive trajectories
This substudy uses a modified version of the Brief Test 
of Adult Cognition by Telephone to determine the rate 
of postoperative cognitive recovery and how delirium 
impacts cognitive recovery via interval assessments up 
to 6 months after surgery.175 176 The battery will evaluate 
multiple cognitive domains including episodic memory, 
working memory, processing speed, attention and exec-
utive function. Associations between EEG measures and 
cognitive function will also be evaluated.
Automated sleep staging
Staging provided by the manufacturer’s automated algo-
rithm will be compared with the manual sleep staging 
performed by registered PSG technologists.
Relationship of sleep structure to clinical outcomes
Preoperative EEG/sleep measures, sleep surveys (Epworth 
Sleepiness Scale, STOP BANG) and Geriatric Depression 
Scale scores will be evaluated against secondary postoper-
ative clinical outcomes, including 30- day mortality, ICU 
length of stay, depression, atrial fibrillation and acute and 
persistent pain scores.
Comparisons of sleep and sleep-like EEG markers
Within- subject comparisons will be made between EEG 
markers spanning different states of arousal.
Utility of intraoperative EEG markers
Intraoperative EEG measures, including burst suppres-
sion will be evaluated against postoperative outcomes.
DISCUSSION
The P- DROWS- E study aims to enhance our under-
standing of perioperative delirium. We will use EEG 
recordings acquired across different states of arousal in 
tandem with serial perioperative delirium assessments to 
determine temporal associations between EEG markers 
and postoperative delirium outcomes. Our work is 
enhanced by integrating additional data including assess-
ments of cognition and clinical variables (figure 4). As a 
result, we are well positioned to develop analytical models 
for predictive and diagnostic EEG markers of postopera-
tive delirium.
Until recently, technical limitations have impeded 
incisive probing of the relationships between sleep 
architecture and postoperative delirium. Our study uses 
a battery- operated, portable device that is specifically 
designed for continuous long- term EEG recordings 
with minimal need for direct assistance by staff. This 
approach should greatly enhance patient participation, 
tolerance and comfort while posing minimal interfer-
ence to postoperative sleep and rehabilitation. The EEG 
Figure 4 Prognosticating Delirium Recovery Outcomes Using Wakefulness and Sleep Electroencephalography study overview. 
CAM, confusion assessment method; EEG, electroencephalography; PDR, posterior dominant rhythm; SWA, slow wave activity.
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device, however, is not without limitations. Dry electrodes 
allow comfort and easy instrumentation, but they may be 
more prone to artefacts related to poor skin adherence. 
Thus, expertise and vigilance are required to differen-
tiate EEG waveforms from artefact to fulfil the promise 
of this technological advance for large scale clinical sleep 
investigations. Another potential confounder for EEG 
interpretation and delirium outcomes includes the use 
of anaesthetics and opioids that may contribute poorly 
controlled sample variance in our study population. 
Nevertheless, P- DROWS- E will be an important early step 
in identifying prognostic associations between EEG and 
postoperative delirium.
Application of findings and future directions
P- DROWS- E may yield EEG applications that are signif-
icant and far- reaching. The potential to better identify 
patients at risk for postoperative delirium and track their 
disorder quantitatively would advance perioperative and 
critical care medicine. The study also has important mech-
anistic implications for modulating sleep and wakefulness 
that have bearing on sedation and analgesic strategies in 
procedural medicine. Finally, the use of wireless wearable 
devices for monitoring brain activity is proof- of- principle 
for implementing neural telemetry in vulnerable popula-
tions in the future.
ETHICS AND DISSEMINATION
The study design, study procedures and informed 
consent procedure were approved by the ethics board at 
Washington University, and the study will be carried out 
in compliance with the Declaration of Helsinki. All partic-
ipants will provide informed consent (see online supple-
mental file 2).
Any protocol modifications, which may impact study 
procedures, administrative aspects or patient safety, 
will require a formal amendment to the protocol. Such 
amendments will be approved by the Institutional Review 
Board prior to implementation. The study will not have 
a data monitoring committee given that we do not antic-
ipate severe adverse events and was not required for 
our study by the Institutional Review Board. To ensure 
the conduct of quality research, the Washington Univer-
sity School of Medicine IRB regularly conducts audits of 
research studies. Dissemination plans include presenta-
tions at scientific conferences, scientific publications and 
mass media.
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12-13, Figure 3 
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generation 
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factors for stratification. To reduce predictability of a random sequence, details of any planned restriction 
(eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants 





16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, 
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BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open




18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related 
processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of 
study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. 
Reference to where data collection forms can be found, if not in the protocol 
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 18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be 
collected for participants who discontinue or deviate from intervention protocols 
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Data management 19 Plans for data entry, coding, security, and storage, including any related processes to promote data quality 
(eg, double data entry; range checks for data values). Reference to where details of data management 
procedures can be found, if not in the protocol 
Supplementary 
File 2 
Statistical methods 20a Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the 
statistical analysis plan can be found, if not in the protocol 
15-18 
 20b Methods for any additional analyses (eg, subgroup and adjusted analyses) 19-20 
 20c Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any 





Data monitoring 21a Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of 
whether it is independent from the sponsor and competing interests; and reference to where further details 
about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not 
needed 
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 21b Description of any interim analyses and stopping guidelines, including who will have access to these interim 
results and make the final decision to terminate the trial 
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Harms 22 Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse 
events and other unintended effects of trial interventions or trial conduct 
Supplementary 
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Auditing 23 Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent 
from investigators and the sponsor 
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Ethics and dissemination  
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24 Plans for seeking research ethics committee/institutional review board (REC/IRB) approval 23 
Protocol 
amendments 
25 Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, 
analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, 
regulators) 
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Consent or assent 26a Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and 
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 26b Additional consent provisions for collection and use of participant data and biological specimens in ancillary 
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28 Financial and other competing interests for principal investigators for the overall trial and each study site 23 
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Dissemination policy 31a Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, 
the public, and other relevant groups (eg, via publication, reporting in results databases, or other data 
sharing arrangements), including any publication restrictions 
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 31b Authorship eligibility guidelines and any intended use of professional writers 23 
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Appendices 
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33 Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular 
analysis in the current trial and for future use in ancillary studies, if applicable 
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INFORMED CONSENT DOCUMENT 
 
Project Title: P-DROWS-E / Prognosticating Delirium Recovery Outcomes Using Wakefulness 
and Sleep Electroencephalography 
 
Principal Investigator: Ben J.A. Palanca, MD, PhD, MSc 
 
Research Team Contact: Thomas Nguyen, Nguyen.t@wustl.edu, 314-273-2454 
 
This consent form describes the research study and helps you decide if you want to participate.  It 
provides important information about what you will be asked to do during the study, about the risks and 
benefits of the study, and about your rights and responsibilities as a research participant. By signing this 
form, you are agreeing to participate in this study. 
• You should read and understand the information in this document including the procedures, 
risks and potential benefits.  
• If you have questions about anything in this form, you should ask the research team for more 
information before you agree to participate.   
• You may also wish to talk to your family or friends about your participation in this study. 
• Do not agree to participate in this study unless the research team has answered your 
questions and you decide that you want to be part of this study.  
 
WHAT IS THE PURPOSE OF THIS STUDY? 
This is a research study.  We invite you to participate in this research study because you are going to 
undergo a cardiac surgical procedure. We want to understand your sleep and brain function before, 
during, and after surgery. 
 
Postoperative delirium is a condition in which patients develop temporary difficulties in maintaining 
attention and thinking clearly. These new problems can appear after surgery and change throughout the 
day. This confusion can last several days. 
 
The overall purpose of this study is to measure brain activity during sleep and wakefulness to learn 
about their relationships to delirium after surgery. While you may not feel like your normal self during 
the study, you are in the best position to help us learn how to improve the recovery of brain function and 
sleep in others having surgery. We need to learn from those who have and have not become confused 
after their surgical procedure. 
 
WHAT WILL HAPPEN DURING THIS STUDY? 
Your participation in this study involves the study of your brain activity at three periods: (1) 1-2 days 
within the weeks before you undergo surgery, (2) during surgery, and (3) for up to 7 days after you have 
had surgery. We may also contact you after hospital discharge to study your thinking abilities. This 
research study will take place at home and at the Washington University School of Medicine campus.  
 
Recording Before Surgery: The research team will show you how to wear a lightweight headband for the 
study. This device, the DREEM is used to assess sleep quality at home. It will allow us to record brain 
electrical activity from your scalp, using electroencephalography, or EEG. EEG is currently used to 
study brain function in the operating room and for assisting in the diagnosis of sleep problems.  
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First, we will show you the DREEM, and how to wear it. After we show you an instruction card, we will 
determine the best fit for wearing the device. We will then have you wear the DREEM so that we may 
obtain baseline data. We will then ask you to stay awake with your eyes closed and open. We may ask 
you to do some simple tasks, such as wiggling your toes or tapping your fingers. The research team will 
also ask you some questions about any pain you are experiencing and how you are thinking and feeling. 
You will also be asked to complete a short cognitive assessment and fill out surveys regarding your 
quality of sleep and sleep habits, how sleepy you feel during various activities, your mood, and some 
basic demographic information. We will then send you home with the DREEM to wear while you sleep 
for 1-2 nights before you have surgery. We will call you before and after every day of recording to assist 
you in this process.  
 
We will ask you to bring the DREEM back on the day of surgery. Alternatively, if you are in the 
hospital on the night before surgery, we will help you wear it and discuss with your nurses and doctors 
how it will not impede their care for you. 
 
Alternate Operations Due to COVID-19: The research team will send a lightweight headband to your 
home. We will email or text you a link to an instructional video to show you how to use the device and a 
link to complete our surveys electronically. Before going to sleep, you will be asked to stay awake with 
your eyes open for 4 minutes followed by eyes closed for 4 minutes while wearing the headband. We 
will contact you before and after each day of recording to assist you in this process. Depending on your 
convenience, we will ask you to bring the DREEM back on the day of surgery or ship the device back to 
us using a prepaid shipping package.  
 
Recording During Surgery: Before you go into surgery, a member of the research team will help you 
wear the DREEM. We may ask you to remain awake with your eyes open and closed for a few minutes 
before you wear it throughout your surgery. We will be in contact with your nurses and physicians to 
ensure that the device will not interfere with your care.  
 
Alternate Operations Due to COVID-19: On the day of surgery, we may also you to complete a short 
cognitive assessment before surgery due to limited in-person interaction at baseline.  
 
Recording After Surgery: After your surgery is completed, the research team will check on the device 
and have you continue wearing the DREEM throughout the day and night. This will continue up to the 
first seven days after surgery. The team will ask you more questions about any pain you are 
experiencing and how you are thinking and feeling.   We will again ask you to do simple tasks or to 
otherwise lay still with your eyes closed. Our interaction with you on these days will mainly be around 7 
AM, 1 PM, and 7 PM, and should take roughly 10-30 minutes. At this time, we can also adjust the 
device to improve your comfort if needed.  
 
Outpatient Follow-Up: After you have left the hospital, we may contact you at certain time points to 
assess your thinking. This will be performed by phone or in the hospital. We would do our best to 
coordinate with your clinical follow-up appointments. During these 15-20 minute follow-ups, we will 
ask you to answer a series of questions. We will audio-record these interactions to better interpret your 
responses. If the follow-up is in person, you may be asked to wear the DREEM device during the 
session. 
 
At the above time points and after the study, we will want to check on your satisfaction and determine 
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ways to improve comfort and tolerability, to aid future patients in the study. Additionally, we may 
continually monitor your electronic medical record during your enrollment to help coordinate timing of 
study procedures.  We will also collect information from your electronic medical record pertaining to 
your surgery, recovery progress, and indicators of mental status including delirium. We would continue 
accessing these data after you have been discharged from the hospital.  
 
Will you save my samples or research data to use in future research studies?  
As part of this study, we are obtaining cognitive assessments and EEG data from you. We would like to 
use these data for studies going on right now as well as studies that are conducted in the future. These 
studies may provide additional information that will be helpful in understanding brain recovery after 
surgery or other diseases or conditions, including research to develop investigational tests, treatments, 
drugs or devices that are not yet approved by the U.S. Food and Drug Administration. It is unlikely that 
what we learn from these studies will have a direct benefit to you. There are no plans to provide 
financial compensation to you should this occur.  By allowing us to use your EEG data, you give up any 
property rights you may have in the EEG data. 
 
We will share your data with other researchers. These researchers may be at Washington University, at 
other research centers and institutions, or industry sponsors of research.  We may also share your 
research data with large data repositories (a repository is a database of information) for broad sharing 
with the research community.  If your individual research data is placed in one of these repositories only 
qualified researchers, who have received prior approval from individuals that monitor the use of the 
data, will be able to look at your information.   
 
Your data will be stored without your name or any other kind of link that would enable us to identify 
which sample(s) or data are yours. Therefore, it will be available for use in future research studies 
indefinitely and cannot be removed. 
 
Video Recording/Photographs/Audio Recording 
Part of the study involves videotaping and/or photographing the DREEM headband while it is on your 
head. Video clips and/or photographs of our recording sessions will be used to gauge your brain state, 
allow for prompt intervention in the case of any safety concerns, and for demonstration purposes for 
potential participants.  
 
We will also use the photographs and/or video clippings in future abstract/manuscript submissions or 
academic conferences. It is customary to include photographs or video clips when presenting findings 
using new brain monitoring technologies. No identifiers or personal health information will be 
associated with the photographic or video materials used in publications, beyond the images. Reasonable 
efforts will be made to conceal your identity if the pictures or images are used. Your eyes will be 
covered in photographs to hide your identity.  
 
Video will be stored electronically with an assigned code instead of your name and will be accessible 
only to the research staff on this project. Videos and photos used for education will be kept for 7 years. 
For academic presentations, we will keep the videos/photos indefinitely. Alternatively, they may be 
destroyed upon the participant’s written request. 
 
Additionally, audio recordings may be requested for the cognitive task performance portion of the study. 
These recordings will only contain responses to task items and no identifying information aside from 
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coded subject identifiers. These recordings will be used to further evaluate and verify your cognitive 
performance during certain tasks. 
 
I give you permission to make video recordings/photographs/audio recordings of me during this study. 
 
_____ Yes        _____ No 
Initials  Initials 
 
 
HOW MANY PEOPLE WILL PARTICIPATE? 
Approximately 220 people will take part in this study conducted by investigators at Washington 
University.   
 
HOW LONG WILL I BE IN THIS STUDY? 
Your direct participation in the study will take up to 10 days, with one – two days of recording before 
surgery and seven days of recording during and after surgery. We will contact you within a week after 
your enrollment in the study in person or by telephone to obtain feedback from your experience in the 
study. We would like to determine whether you had any problems during your involvement. We will 
also maintain phone contact in the months after your inpatient stay to coordinate and collect data on 
your thinking abilities. 
 
WHAT ARE THE RISKS OF THIS STUDY? 
You may experience one or more of the risks indicated below from being in this study. In addition to 
these, there may be other unknown risks, or risks that we did not anticipate, associated with being in this 
study.  
 
DREEM EEG [Electroencephalography]: Skin irritation may occur from wearing these electrodes. 
Some discomfort may occur when we change the electrodes, particularly those over your hair.  
 
Questionnaires: There are no risks associated with the questionnaires. 
 
Breach of Confidentiality:  One risk of participating in this study is that confidential information about 
you may be accidentally disclosed.  We will use our best efforts to keep the information about you 
secure.  Please see the section in this consent form titled “How will you keep my information 
confidential?” for more information. 
 
WHAT ARE THE BENEFITS OF THIS STUDY? 
You will not benefit from being in this study. However, we hope that, in the future, other people might 
benefit from this study because the results may increase our understanding of the changes in brain 
function after surgery. 
 
WILL IT COST ME ANYTHING TO BE IN THIS STUDY? 
You will not have any costs for being in this research study. 
 
You and/or your medical/hospital insurance provider will remain responsible for your regular medical 
care expenses. 
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WILL I BE PAID FOR PARTICIPATING? 
You will be paid for being in this research study. You will need to provide your social security number 
(SSN) in order for us to pay you. You may choose to participate without being paid if you do not wish to 
provide your social security number (SSN) for this purpose.  You may also need to provide your address 
if a check will be mailed to you. If your social security number is obtained for payment purposes only, it 
will not be retained for research purposes.    
 
You will be compensated a maximum of $300 for study involvement, depending on when you enter the 
study in relation to your surgery. You will receive $50 for each preoperative (before surgery) recording 
(up to $100 total for two days) for helping us record data while you sleep at home and for bringing the 
device back to us. You will receive $25 for each postoperative study day, including the day of surgery and 
up to seven days after surgery (maximum $200 for eight days).  Cab fare will be arranged and paid for 
ahead of any study-related outpatient visits by study staff to cover the cost of transportation for study 
procedures.  If otherwise requested by the patient, parking vouchers will also be assigned to participants 
to cover the cost of parking for the duration of any required study-related visits. 
 
WHO IS FUNDING THIS STUDY? 
The National Institutes of Health (NIH) is funding this research study.  This means that Washington 
University is receiving payments from NIH to support the activities that are required to conduct the 
study.  No one on the research team will receive a direct payment or increase in salary from NIH for 
conducting this study. 
 
WHAT IF I AM INJURED AS A RESULT OF THIS STUDY? 
Washington University investigators and staff will try to reduce, control, and treat any complications 
from this research. If you feel you are injured because of the study, please contact the investigator (314)-
362-7823) and/or the Washington University Human Research Protection Office at 1-(800)-438-0445.  
 
Decisions about payment for medical treatment for injuries relating to your participation in research will 
be made by Washington University. If you need to seek medical care for a research-related injury, please 
notify the investigator as soon as possible. 
 
HOW WILL YOU KEEP MY INFORMATION CONFIDENTIAL? 
We will keep your participation in this research study confidential to the extent permitted by law.  
However, it is possible that other people such as those indicated below may become aware of your 
participation in this study and may inspect and copy records pertaining to this research.  Some of these 
records could contain information that personally identifies you.  
• Government representatives, (including the Office for Human Research Protections) to complete 
federal or state responsibilities 
• The U.S. Food and Drug Administration 
• The National Institutes of Health 
• Hospital or University representatives, to complete Hospital or University responsibilities 
• Information about your participation in this study may be documented in your health care records 
and be available to your health care providers who are not part of the research team.  
• The last four digits of your social security number may be used in hospital or University systems 
to track billing information for research procedures 
• Washington University’s Institutional Review Board (a committee that oversees the conduct of 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-044295:e044295. 10 2020;BMJ Open, et al. Smith SK
 
 
6/15/2020  Page 6 of 9 
research involving human participants) and the Human Research Protection Office. The 
Institutional Review Board has reviewed and approved this study.  
 
To help protect your confidentiality, we will have all paper documents locked in a filing cabinet in a 
locked office of a member of the study team. We will keep all electronic documents on secured servers 
that are password protected and have various state of the art firewall protections with frequent upgrades 
of these protections. Access to these electronic research files will be restricted to members of the 
research team and will be controlled by the principal investigator.  If we write a report or article about 
this study or share the study data set with others, we will do so in such a way that you cannot be directly 
identified. 
 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S. 
Law. This Web site will not include information that can identify you. At most, the Web site will 
include a summary of the results. You can search this Web site at any time. 
To further protect your privacy, this research is covered by a Certificate of Confidentiality from the 
federal government. This means that the researchers can refuse to disclose information that may identify 
you in any legal or court proceeding or to anyone who is not connected with the research except if:  
• there is a law that requires disclosure, such as to report child abuse and neglect, or harm to self or 
others;  
• you give permission to disclose your information, including as described in this consent form; or 
• it is used for other scientific research allowed by federal law. 
You have the right to share your information or involvement in this study with anyone at any time. You 
may also give the research team permission to disclose your information to a third party or any other 
person not connected with the research.  
 
If information about you or your involvement in this research is placed in your medical record the 
information may no longer be protected under the Certificate. However, information in your medical 
records is protected in other ways.    
 
Are there additional protections for my health information? 
Protected Health Information (PHI) is health information that identifies you. PHI is protected by federal 
law under HIPAA (the Health Insurance Portability and Accountability Act). To take part in this 
research, you must give the research team permission to use and disclose (share) your PHI for the study 
as explained in this consent form.  The research team will follow state and federal laws and may share 
your health information with the agencies and people listed under the previous section titled, “How will 
you keep my information confidential?” 
 
Once your health information is shared with someone outside of the research team, it may no longer be 
protected by HIPAA.   
 
The research team will only use and share your information as talked about in this form or as permitted or 
required by law.  When possible, the research team will make sure information cannot be linked to you 
(de-identified).  Once information is de-identified, it may be used and shared for other purposes not 
discussed in this consent form. If you have questions or concerns about your privacy and the use of your 
PHI, please contact the University’s Privacy Officer at 866-747-4975.  
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• Your employer will have access to any email communications sent or received on any 
electronic devices used for work or through a work server. 
  
Do you agree to allow us to send your health information via email?   
 
_____ Yes  _____ No 
Initials  Initials 
 
 
IS BEING IN THIS STUDY VOLUNTARY? 
Taking part in this research study is completely voluntary.  You may choose not to take part at all.  If 
you decide to be in this study, you may stop participating at any time. Any data that was collected as 
part of your participation in the study will remain as part of the study records and cannot be removed.   
 
If you decide not to be in this study, or if you stop participating at any time, you won’t be penalized or 
lose any benefits for which you otherwise qualify.   
 
What if I decide to withdraw from the study? 
You may withdraw by telling the study team you are no longer interested in participating in the study or 
you may send in a withdrawal letter. A sample withdrawal letter can be found at 
https://hrpo.wustl.edu/participants/withdrawing-from-a-study/ under Withdrawing from a Research 
Study. 
 
Will I receive new information about the study while participating? 
If we obtain any new information during this study that might affect your willingness to continue 
participating in the study, we’ll promptly provide you with that information. 
 
Can someone else end my participation in this study? 
Under certain circumstances, the Principal Investigator (PI) might decide to end your participation in 
this research study earlier than planned.  This might happen for no reason or because you are found to be 
ineligible for the study, or because your involvement causes significant distress/discomfort. 
 
WHAT IF I HAVE QUESTIONS? 
We encourage you to ask questions.  If you have any questions about the research study itself, please 
contact: We encourage you to ask questions.  If you have any questions about the research study itself, 
please contact: 
 
Principal Investigator: Ben Palanca, M.D., Ph.D., M.Sc.  
Mailing Address: Washington University School of Medicine / Department of Anesthesiology / Campus 
Box 8054 / 660 South Euclid Avenue / St. Louis, MO / 63110  
Telephone: 314-273-9076. 
 
If you have questions, concerns, or complaints about your rights as a research participant, please contact 
the Human Research Protection Office at 660 South Euclid Avenue, Campus Box 8089, St. Louis, MO  
63110, 1-(800)-438-0445, or email hrpo@wustl.edu.   General information about being a research 
participant can be found on the Human Research Protection Office web site, http://hrpo.wustl.edu.  To 
offer input about your experiences as a research participant or to speak to someone other than the 
research staff, call the Human Research Protection Office at the number above. 
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This consent form is not a contract. It is a written explanation of what will happen during the study if 
you decide to participate. You are not waiving any legal rights by agreeing to participate in this study. 
As a participant you have rights and responsibilities as described in this document and including: 
• To be given enough time before signing below to weigh the risks and potential benefits and 
decide if you want to participate without any pressure from the research team or others. 
• To understand all of the information included in the document, have your questions answered, 
and receive an explanation of anything you do not understand. 
• To follow the procedures described in this document and the instructions of the research team to 
the best of your ability unless you choose to stop your participation in the research study. 
• To give the research team accurate and complete information. 
• To tell the research team promptly about any problems you have related to your participation, or 
if you are unable to continue and wish to stop participating in the research study. 
 
Your signature indicates that this research study has been explained to you, that your questions have 
been answered, and that you agree to take part in this study.  You will receive a signed and dated copy 
of this form. 
 













Statement of Person Who Obtained Consent 
The information in this document has been discussed with the participant or, where appropriate, with the 
participant’s legally authorized representative.  The participant has indicated that he or she understands 








(Name of Person who Obtained Consent - printed) 
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